Hemoregulatory peptide 5b

Cat. No.: HY-P2158: Data Sheet Handling Instructions
FAQs
Technical Support

Hemoregulatory peptide 5b is an acidic pentapeptide and also a selective inhibitor of myeloid hematopoiesis. Hemoregulatory peptide 5b inhibits myeloid hematopoietic colony formation, as well as the proliferation of committed myeloid hematopoietic stem cells and differentiating myeloid cells. Hemoregulatory peptide 5b exerts anticancer effects against mouse breast cancer and rat glioma. Hemoregulatory peptide 5b exhibits dose-dependent complex hematopoietic regulatory effects in vivo. Hemoregulatory peptide 5b can be used in research related to breast cancer, glioma, and lymphoma.

For research use only. We do not sell to patients.

Hemoregulatory peptide 5b Chemical Structure

CAS No. : 84588-89-6

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Hemoregulatory peptide 5b (1 nM-10 μM; 4-5 days) exerts a slight but statistically significant inhibitory effect on the proliferation of mouse 3T3 fibroblasts starting at a concentration of 1 nM^[1].
Hemoregulatory peptide 5b (batch 2) (10^-13-10^-4 mol/L; 1 h preincubation) potently inhibits myeloid colony formation in bone marrow cells of C3H mice, with an optimal inhibitory concentration of 10^-9 mol/L; it exerts no inhibitory effect at concentrations above 10^-5 mol/L, and stimulates colony formation at a concentration of 10^-4 mol/L^[2].
Hemoregulatory peptide 5b (0.01 nM-1 mM; 24 h) shows no toxicity to mouse bone marrow cells in vitro^[3].
Hemoregulatory peptide 5b (10 nM) inhibits committed myeloid stem cells (CFUc) in vitro^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	mouse 3T3 fibroblasts
Concentration:	1×10^-9 M, 1×10^-7 M, 1×10^-5 M
Incubation Time:	4 days, 5 days, up to confluency
Result:	Exerted moderate inhibitory effect at day 4 for concentrations from 1×10^-9 to 1×10^-5 M. Showed slight, statistically significant (p ≤ 0.05) inhibition at day 5 and confluency.

In Vivo

Hemoregulatory peptide 5b (120 μg-1.2 mg; i.p.; s.c.; single injection; consecutive administration for 9 days; continuous infusion for 6-19 days) dose-dependently regulates the peripheral blood leukocyte count in normal female C3H mice: moderate doses (120 μg single injection, infusion at 14 μg/h for 6 days) reduce granulocyte counts; a single high-dose injection (1.2 mg) produces only a transient effect; while long-term high-dose infusion (infusion at 14 μg/h for 19 days) increases counts of granulocytes, monocytes and lymphocytes^[3].
Hemoregulatory peptide 5b (0.12 μg-9.1 mg per mouse; i.p., s.c.; single injection, 9 injections, continuous infusion; 1-19 days) regulates myeloid and erythroid hematopoietic cells in mouse bone marrow in a dose-dependent and administration route-dependent manner: low doses inhibit myeloid hematopoiesis, a single injection of high dose inhibits erythroid hematopoiesis, while continuous infusion of high dose reduces mature myeloid hematopoietic cells and increases peripheral blood granulocytes^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C₃H mice (female, SPF quality, 20-24 g)^[4]
Dosage:	0.12 μg per mouse (9 injections); 120 μg per mouse (1 injection); 120 μg per mouse (9 injections); 1.2 mg per mouse (1 injection); 0.14 μg/h (total 28 μg per mouse, 7-day infusion); 14 μg/h (total 2.8 mg per mouse, 7-day infusion); 14 μg/h (total 9.1 mg per mouse, 19-day infusion)
Administration:	i.p. (9 injections); i.p. (single injection); s.c. (continuous infusion, 7 days); s.c. (continuous infusion, 19 days, minipumps replaced weekly)
Result:	Reduced total myelopoietic cells per femur to 89% of control and proliferative myelopoietic cells to 77% of control (P < 0.05), while non-proliferative myelopoietic cells and erythropoietic cells remained unchanged relative to control with 9 injections of 0.12 μg. Reduced total myelopoietic cells per femur to 86% of control, proliferative myelopoietic cells to 79% of control (P < 0.05), non-proliferative myelopoietic cells to 96% of control, and increased erythropoietic cells to 155% of control (P < 0.01) 2 days post single injection of 120 μg. Reduced total myelopoietic cells per femur to 73% of control (P < 0.01), proliferative myelopoietic cells to 62% of control (P < 0.01), and increased erythropoietic cells to 114% of control, while non-proliferative myelopoietic cells remained unchanged relative to control 7 days after the last of 9 injections of 120 μg. Reduced erythropoietic cells per femur to 68% of control (P < 0.01), abolished the normal circadian increase in myelopoietic cell numbers, and kept total myelopoietic cell numbers similar to control 24 hours post single injection of 1.2 mg. Increased proliferative myelopoietic cells per femur to 125% of control (P < 0.05), while all other cell populations showed no significant changes relative to control during or after infusion with continuous 0.14 μg/h s.c. infusion for 7 days. Increased non-proliferative myelopoietic cells per femur to 135% of control (P < 0.05) and reduced erythropoietic cells to 66% of control (P < 0.05) during continuous 14 μg/h s.c. infusion for 7 days; kept erythropoietic cells reduced to 67% of control (P < 0.05) 6 days post-infusion; returned all cell populations to control levels 12 days post-infusion. Reduced non-proliferative myelopoietic cells per femur to 66% of control (P < 0.01), kept all other bone marrow cell populations unchanged relative to control, and nearly doubled peripheral blood granulocyte numbers with continuous 14 μg/h s.c. infusion for 19 days.

Molecular Weight

604.63

Formula

C₂₃H₃₆N₆O₁₁S

CAS No.

84588-89-6

Sequence

{Pro(5-oxo)}-Glu-Asp-Cys-Lys

Sequence Shortening

{Pro(5-oxo)}-EDCK

SMILES

[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(O)=O)=O)CS)=O)(NC([C@@H](NC(=O)[C@@H]1CCC(=O)N1)CCC(O)=O)=O)CC(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Laerum OD, et al. Selectivity of hemoregulatory peptide (HP5b) action in culture. International journal of cell cloning. 1990 Nov;8(6):431-44.

[2]. Kreja L, et al. Effects of a hemoregulatory peptide (HP5b) on erythroid and myelopoietic colony formation in vitro. Scandinavian journal of haematology. 1986 Aug;37(2):79-86.

[3]. Laerum OD, et al. Peripheral blood leukocyte alterations in mice induced by a hemoregulatory pentapeptide (HP 5b). Leuk Res. 1985;9(8):1075-84.

[4]. Laerum OD, et al. Modulation of murine hemopoiesis in vivo by a synthetic hemoregulatory pentapeptide (HP 5b). Differentiation. 1984;27(2):106-12.